CY1107830T1 - Αντικαρκινικα αναλογα - Google Patents
Αντικαρκινικα αναλογαInfo
- Publication number
- CY1107830T1 CY1107830T1 CY20071101576T CY071101576T CY1107830T1 CY 1107830 T1 CY1107830 T1 CY 1107830T1 CY 20071101576 T CY20071101576 T CY 20071101576T CY 071101576 T CY071101576 T CY 071101576T CY 1107830 T1 CY1107830 T1 CY 1107830T1
- Authority
- CY
- Cyprus
- Prior art keywords
- substituted
- unsubstituted
- cancer
- analogues
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Παράγωγα της εκτεϊνασκιδίνης 736 του γενικού χημικού τύπου (I) όπου οι ομάδες R1,R2, R3, R4 και R5 επιλέγονται ανεξάρτητα από την ομάδα που περιλαμβάνει τα Η, OH, OR', SH, SR', SOR', SO2R', C(=O)R', C(=O)OR', NO2, NH2, NHR', N(R')2, NHC(O)R', CN, αλογόνο, =O, υποκατεστημένο ή μη υποκατεστημένο αλκύλιο C1-C25, υποκατεστημένο ή μη υποκατεστημένο αλκενύλιο C2-C18, υποκατεστημένο ή μη υποκατεστημένο αλκυνύλιο C2-C18, υποκατεστημένο ή μη υποκατεστημένο αρύλιο, υποκατεστημένο ή μη υποκατεστημένο ετεροκυκλικό, όπου το Χ επιλέγεται ανεξάρτητα από τα OR', CN, (=O), ή Η, όπου κάθε μία από τις ομάδες R' επιλέγεται ανεξάρτητα από την ομάδα που περιλαμβάνει τα Η, OH, ΝO2, ΝΗ2, SH, CN, αλογόνο, =O, C(=O)H, C(=O)CH3, CO2H, υποκατεστημένο ή μη υποκατεστημένο αλκύλιο C1-C25, υποκατεστημένο ή μη υποκατεστημένο αλκενύλιο C2-C18, υποκατεστημένο ή μη υποκατεστημένο αλκυνύλιο C2-C18, υποκατεστημένο ή μη υποκατεστημένο αρύλιο, όπου το m είναι Ο, 1 ή 2 και όπου το n είναι 0, 1, 2, 3, ή 4, και η χρήση τους ως αντικαρκινικός παράγοντας.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0119243.4A GB0119243D0 (en) | 2001-08-07 | 2001-08-07 | Antitumoral analogs of ET-743 |
| EP02753134A EP1414828B9 (en) | 2001-08-07 | 2002-08-06 | Antitumoral analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107830T1 true CY1107830T1 (el) | 2013-06-19 |
Family
ID=9919954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071101576T CY1107830T1 (el) | 2001-08-07 | 2007-12-12 | Αντικαρκινικα αναλογα |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7763615B2 (el) |
| EP (3) | EP1806349A1 (el) |
| JP (2) | JP4684552B2 (el) |
| KR (1) | KR20040032150A (el) |
| CN (1) | CN100334094C (el) |
| AT (1) | ATE374777T1 (el) |
| AU (1) | AU2002313540B2 (el) |
| CA (1) | CA2455768C (el) |
| CY (1) | CY1107830T1 (el) |
| DE (1) | DE60222775T2 (el) |
| DK (1) | DK1414828T3 (el) |
| ES (1) | ES2294151T3 (el) |
| GB (1) | GB0119243D0 (el) |
| HK (1) | HK1065786A1 (el) |
| HU (1) | HU229779B1 (el) |
| IL (2) | IL160051A0 (el) |
| MX (1) | MXPA04001240A (el) |
| NO (1) | NO337476B1 (el) |
| NZ (1) | NZ530837A (el) |
| PL (1) | PL218295B1 (el) |
| PT (1) | PT1414828E (el) |
| RU (1) | RU2283842C2 (el) |
| WO (1) | WO2003014127A1 (el) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0202544D0 (en) * | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| KR101614723B1 (ko) | 2008-01-11 | 2016-04-22 | 알바니 몰레큘라 리써치, 인크. | Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌 |
| JP2012532144A (ja) * | 2009-07-01 | 2012-12-13 | アルバニー モレキュラー リサーチ， インコーポレイテッド | アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用 |
| US8629158B2 (en) * | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| US8618299B2 (en) * | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
| WO2011003021A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| ES2534331T3 (es) * | 2010-05-25 | 2015-04-21 | Pharma Mar S.A. | Proceso sintético para la producción de compuestos e intermedios de ecteinascidina |
| BR122017028570B1 (pt) | 2010-11-12 | 2022-03-03 | Pharma Mar, S.A | Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit |
| ES2589702T3 (es) | 2010-11-26 | 2016-11-15 | Nec Corporation | Dispositivo, método y programa de descodificación de video |
| WO2012088124A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof |
| WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
| WO2017067670A1 (en) | 2015-10-23 | 2017-04-27 | Pharmathen S.A. | A novel process for the preparation of tryptamines and derivatives thereof |
| JOP20190254A1 (ar) * | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| TWI824043B (zh) * | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | 藥物抗體共軛物 |
| WO2021043949A1 (en) | 2019-09-03 | 2021-03-11 | Pharma Mar S.A. | Lurbinectedin in the treatment of malignant mesothelioma |
| CN112574234B (zh) * | 2019-09-27 | 2022-05-24 | 江苏恒瑞医药股份有限公司 | 一种海鞘素衍生物的制备方法 |
| WO2021228414A1 (en) | 2020-05-14 | 2021-11-18 | Pharma Mar, S.A. | Methods of treating small cell lung cancer with lurbinectedin formulations |
| JOP20220118A1 (ar) | 2019-11-21 | 2023-01-30 | Pharma Mar Sa | طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين |
| MA56827B2 (fr) | 2019-11-21 | 2023-09-27 | Pharma Mar Sa | Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine |
| JP2023522259A (ja) | 2020-04-21 | 2023-05-29 | ファルマ、マール、ソシエダード、アノニマ | 薬物抗体コンジュゲート |
| WO2021218896A1 (zh) * | 2020-04-26 | 2021-11-04 | 江苏恒瑞医药股份有限公司 | 海鞘素类衍生物及其制备方法与医药用途 |
| CA3191207A1 (en) | 2020-09-04 | 2022-03-10 | Guido Kroemer | Combination of lurbinectedin and immune checkpoint inhibitor |
| WO2022101255A1 (en) | 2020-11-10 | 2022-05-19 | Pharma Mar, S.A. | Lurbinectedin and irinotecan combinations |
| CA3229559A1 (en) * | 2021-08-31 | 2023-03-09 | Srinivasa Chary CHINTALAPATI | Novel crystalline polymorph of lurbinectedin and improved process for the preparation of lurbinectedin |
| CA3237009A1 (en) | 2021-11-08 | 2023-05-11 | Luis Gonzaga PAZ-ARES RODRIGUEZ | Lurbinectedin and atezolizumab combinations |
| CN115246846A (zh) * | 2021-11-19 | 2022-10-28 | 江苏慧聚药业股份有限公司 | 卢比替定新晶型及其制备 |
| CN115304619A (zh) * | 2022-04-08 | 2022-11-08 | 上海皓元医药股份有限公司 | 一种卢比替定的晶型及其制备方法 |
| CN114940682A (zh) * | 2022-05-18 | 2022-08-26 | 博瑞制药(苏州)有限公司 | 芦比替定的晶型及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59225189A (ja) | 1983-06-03 | 1984-12-18 | Shionogi & Co Ltd | キノナミン誘導体およびその製造法 |
| JPS6084288A (ja) | 1983-10-13 | 1985-05-13 | Shionogi & Co Ltd | シアノキノナミンアセテ−ト類およびその製造法 |
| AU589282B2 (en) | 1986-06-09 | 1989-10-05 | University Of Illinois | Ecteinascidins 729, 743, 745, 759a, 759b and 770 |
| US5149804A (en) | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
| US5256663A (en) | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
| US5089273A (en) | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
| US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| US5721362A (en) * | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
| US5985876A (en) * | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| PT1067933E (pt) | 1998-04-06 | 2007-11-15 | Univ Illinois | Ecteinascidinas semi-sintéticas |
| HUP0101960A3 (en) | 1998-05-11 | 2003-03-28 | Pharma Mar Sa | Metabolites of ecteinascidin 743, their use and pharmaceutical compositions containing them |
| US6124292A (en) * | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
| MY130271A (en) | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
| JP2003520801A (ja) * | 2000-01-19 | 2003-07-08 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成 |
| CZ304749B6 (cs) * | 2000-04-12 | 2014-09-24 | Pharma Mar, S. A. | Ecteinascidin mající pět spojených kruhů s 1,4-můstkem, farmaceutický prostředek, použití a způsob |
| MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
-
2001
- 2001-08-07 GB GBGB0119243.4A patent/GB0119243D0/en not_active Ceased
-
2002
- 2002-08-06 AU AU2002313540A patent/AU2002313540B2/en active Active
- 2002-08-06 EP EP07001308A patent/EP1806349A1/en not_active Ceased
- 2002-08-06 ES ES02753134T patent/ES2294151T3/es not_active Expired - Lifetime
- 2002-08-06 PT PT02753134T patent/PT1414828E/pt unknown
- 2002-08-06 EP EP02753134A patent/EP1414828B9/en not_active Expired - Lifetime
- 2002-08-06 NZ NZ530837A patent/NZ530837A/en not_active IP Right Cessation
- 2002-08-06 WO PCT/GB2002/003592 patent/WO2003014127A1/en active IP Right Grant
- 2002-08-06 HU HU0401174A patent/HU229779B1/hu unknown
- 2002-08-06 EP EP10180740A patent/EP2270018A1/en not_active Withdrawn
- 2002-08-06 MX MXPA04001240A patent/MXPA04001240A/es active IP Right Grant
- 2002-08-06 IL IL16005102A patent/IL160051A0/xx unknown
- 2002-08-06 CA CA2455768A patent/CA2455768C/en not_active Expired - Lifetime
- 2002-08-06 DK DK02753134T patent/DK1414828T3/da active
- 2002-08-06 JP JP2003519076A patent/JP4684552B2/ja not_active Expired - Lifetime
- 2002-08-06 DE DE60222775T patent/DE60222775T2/de not_active Expired - Lifetime
- 2002-08-06 PL PL367940A patent/PL218295B1/pl unknown
- 2002-08-06 KR KR10-2004-7001924A patent/KR20040032150A/ko active Search and Examination
- 2002-08-06 AT AT02753134T patent/ATE374777T1/de active
- 2002-08-06 CN CNB028196511A patent/CN100334094C/zh not_active Expired - Lifetime
- 2002-08-06 RU RU2004106617/04A patent/RU2283842C2/ru active
- 2002-08-06 US US10/485,536 patent/US7763615B2/en active Active
-
2004
- 2004-01-26 IL IL160051A patent/IL160051A/en active IP Right Grant
- 2004-03-05 NO NO20040961A patent/NO337476B1/no not_active IP Right Cessation
- 2004-10-29 HK HK04108496A patent/HK1065786A1/xx not_active IP Right Cessation
-
2007
- 2007-12-12 CY CY20071101576T patent/CY1107830T1/el unknown
-
2010
- 2010-09-17 JP JP2010209928A patent/JP2011026331A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107830T1 (el) | Αντικαρκινικα αναλογα | |
| NL350077I1 (nl) | Cyprosulfamide | |
| CY1108254T1 (el) | Ενωσεις που επηρεαζουν τη γλυκοκιναση | |
| CY1116298T1 (el) | Ενωσεις 3,4-διυποκατεστημενου 1η-πυραζολιου και χρηση αυτων ως ρυθμιστες κινασων που εξαρτωνται απο κυκλινη (cdk) και κινασης-3 συνθασης γλυκογονου (gsk-3) | |
| DK1117297T3 (da) | Syntetiske analoger af ecteinascidin-743 | |
| CY1105797T1 (el) | Ν-αρυλ-2-οχαζολιδινονο-5-καρβοξαμιδια και παραγωγα αυτων και χρηση αυτων σαν αντιβιοτικα | |
| CY1107978T1 (el) | Νeα παρaγωγα πυριδαζiν -3 (2h) - oνης | |
| CY1104991T1 (el) | Ετεροκυκλικες ενωσεις για χρηση στην αγωγη διαταραχων της ουροποιητικης οδου | |
| DK1412354T3 (da) | Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter | |
| CY1109283T1 (el) | Παραγωγα βαριολινης ως αντικαρκινικα μεσα | |
| CY1108148T1 (el) | Αβερμεκτινης- και μονοσακχαριτη αβερμεκτινης παραγωγα υποκατεστημενα στην 4''- ή 4'- θεση που εχουν ζιζανιοκτονες ιδιοτητες | |
| CY1113359T1 (el) | Αντι-νεοπλασιακα παραγωγα του et-743 | |
| IT1315267B1 (it) | Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale | |
| FI923050A0 (fi) | Nya benzomorfaner och deras anvaendning som laekemedel. | |
| HUP0402341A2 (hu) | Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére | |
| NO20040113L (no) | Variolinderivater og deres anvendelse som antitumormidler | |
| BR0111505A (pt) | Compostos antitumorais | |
| DE69409774D1 (de) | Neue kardioaktive 17-Iminomethylalkenyl-5-beta-14-beta-androstan und 17-Iminoalkyl-5-beta, 14-beta-androstan Derivate, ein Verfahren zu ihrer Herstellung und pharmazeutische Präparate davon | |
| ITTO20020674A1 (it) | Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico | |
| BR0108448A (pt) | Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor | |
| DK1532139T3 (da) | Totalsyntese af myriaporoner |